| Title: |
Impact of a serotonergic lesion on the expression of motor and neuropsychiatric symptoms ; Implication de la sérotonine dans l'expression de troubles moteurs et neuropsycho-comportementaux dans la maladie de Parkison |
| Authors: |
Millot, Mathilde |
| Contributors: |
Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 (ISC-MJ); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS); Université de Lyon; Véronique Sgambato-Faure |
| Source: |
https://theses.hal.science/tel-02557799 ; Neurosciences. Université de Lyon, 2019. Français. ⟨NNT : 2019LYSE1100⟩. |
| Publisher Information: |
CCSD |
| Publication Year: |
2019 |
| Collection: |
HAL Lyon 1 (University Claude Bernard Lyon 1) |
| Subject Terms: |
Dopamine; Serotonin; MPTP; MDMA; Fluoxetine; Pramipexole; Motor and non-motor symptoms; Parkinson’s disease; Symptômes moteurs et non-moteurs; Fluoxétine; Sérotonine; Maladie de Parkinson; [SCCO.NEUR]Cognitive science/Neuroscience |
| Description: |
Parkinson’s disease (PD) is characterized by a progressive and irreversible degeneration of dopaminergic (DA) neurons localized in the substantia nigra, leading to a loss of dopamine within the target structures. When the loss of DA reaches 60 to 80 %, PD patients develop a wide range of motor (rigidity, tremor, akinesia fro example) and non-motor (depression, anxiety, apathy for example) symptoms. Dopatherapy allows the reduction of symptoms expression. But some motor and non-motor symptoms are not counteracted by those DA drugs. In addition to DA degeneration, patients present an early serotonergic (5-HT) lesion. This lesion is linked to the severity of some motor and non-motor symptoms. However, there is no causal link established between 5-HT lesion and parkinsonian symptoms. Therefore, it was essential to determine the role of 5-HT 1) in the expression of motor and non-motor symptoms 2) and in the response of DA and 5-HT treatments. For that, we used a new monkey model of PD, exhibiting a 5-HT lesion (with MDMA ‘”ecstasy”)) followed by a DA lesion (with MPTP). This model allowed us to evaluate the impact of an early 5-HT lesion on parkinsonian symptoms. We used different approaches: PET imaging, pharmacology, behavioral and neuroanatomy. The MDMA-driven early 5-HT lesion induced an anxious-like behavior on MDMA treatedmonkeys. This behavioral modification was not counteracted by 5-HT drugs (antidepressant). This MDMA lesion has also increased the severity and the progression of parkinsonian symptoms induced by DA lesion with MPTP ; La maladie de Parkinson (MP) se caractérise par une dégénérescence progressive et irréversible des neurones dopaminergiques de la substance noire induisant une perte de dopamine (DA) dans les structures cibles. Lorsque cette perte DA se situe entre 60 % et 80 %, les patients présentent des symptômes moteurs (rigidité, tremblement, akinésie) et non-moteurs très variés (dépression, anxiété, apathie). Ces derniers apparaissent avant et/ou en même temps que les symptômes moteurs. La ... |
| Document Type: |
doctoral or postdoctoral thesis |
| Language: |
French |
| Relation: |
NNT: 2019LYSE1100 |
| Availability: |
https://theses.hal.science/tel-02557799; https://theses.hal.science/tel-02557799v1/document; https://theses.hal.science/tel-02557799v1/file/TH2019MILLOTMATHILDE.pdf |
| Rights: |
https://about.hal.science/hal-authorisation-v1/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.16E6CEA0 |
| Database: |
BASE |